Patel Jitendra, Roy Harekrishna, Chintamaneni Pavan Kuma, Patel Rukmani, Bohara Raghvendra
Datta Meghe College of Pharmacy, Datta Meghe Institute of Higher Education (Deemed to be University), Sawangi (Meghe), Wardha 442001, Maharashtra, India.
Department of Pharmaceutics, Nirmala College of Pharmacy, Mangalagiri 522503, Andhra Pradesh, India.
ACS Biomater Sci Eng. 2025 May 12;11(5):2528-2549. doi: 10.1021/acsbiomaterials.5c00004. Epub 2025 Apr 11.
Liver disorders like hepatitis, cirrhosis, and hepatocellular carcinoma present a significant global health challenge, with high morbidity and mortality rates. Key factors contributing to liver disorders include inflammation, oxidative stress, and apoptosis. Due to their multifaceted action, natural compounds are promising candidates for mitigating liver-related disorders. Research studies revealed the antioxidant, anti-inflammatory, and detoxifying properties of natural compounds like curcumin, glycyrrhizin, and silymarin and their potential for liver detoxification and protection. With advancements in nanotechnology in drug delivery, natural compounds have improved stability and targetability, thereby enhancing their bioavailability and therapeutic efficiency. Further, recent advancements in genomics and an increased understanding of genetic factors influencing liver disorders and the hepatoprotective effects of natural agents made way for personalized medicine. Moreover, combinatorial therapy with natural products, synthetic drugs, or other natural agents has improved therapeutic outcomes. Even though clinical trials have confirmed the efficiency of natural compounds as hepatoprotective agents, several challenges remain unanswered in their translation to clinical practice. Therefore, it is logical to integrate natural compounds with nanotechnology and genomics to further advance hepatoprotection. This review gives an overview of the substantial progress made in the field of hepatoprotection, with specific emphasis on natural compounds and their integration with nanotechnology and genomics. This provides valuable insights for future research and innovations in developing therapeutic strategies for liver disorders.
肝炎、肝硬化和肝细胞癌等肝脏疾病是一项重大的全球健康挑战,发病率和死亡率都很高。导致肝脏疾病的关键因素包括炎症、氧化应激和细胞凋亡。由于其多方面的作用,天然化合物有望减轻肝脏相关疾病。研究揭示了姜黄素、甘草酸和水飞蓟素等天然化合物的抗氧化、抗炎和解毒特性,以及它们在肝脏解毒和保护方面的潜力。随着药物递送纳米技术的进步,天然化合物的稳定性和靶向性得到改善,从而提高了它们的生物利用度和治疗效果。此外,基因组学的最新进展以及对影响肝脏疾病的遗传因素和天然药物的肝脏保护作用的进一步了解,为个性化医学开辟了道路。此外,天然产物、合成药物或其他天然药物的联合治疗改善了治疗效果。尽管临床试验已经证实了天然化合物作为肝脏保护剂的有效性,但在将其转化为临床实践方面仍有几个问题尚未得到解答。因此,将天然化合物与纳米技术和基因组学相结合以进一步推进肝脏保护是合乎逻辑的。本综述概述了肝脏保护领域取得的重大进展,特别强调了天然化合物及其与纳米技术和基因组学的整合。这为未来开发肝脏疾病治疗策略的研究和创新提供了有价值的见解。
Eur J Med Chem. 2018-1-8
Acta Pharmacol Sin. 2015-2
Eur J Med Chem. 2013-3-4
Basic Clin Pharmacol Toxicol. 2025-6
Pharm Biol. 2011-5-19
J Clin Transl Hepatol. 2023-12-28
Antioxidants (Basel). 2023-11-22
BMC Complement Med Ther. 2023-10-26